Trial Profile
Phase I trial of CC-223 activity in hormone receptor positive (HR+) breast cancer patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2014
Price :
$35
*
At a glance
- Drugs Onatasertib (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 22 Apr 2014 New trial record